polyethylen
glycol
peg
one
versatil
polym
synthes
amphiphil
chemic
inert
polym
consist
repeat
unit
ethylen
oxid
arrang
either
linear
branch
configur
creat
seri
compound
differ
molecular
weight
uniqu
properti
demonstr
lack
immunogen
toxic
antigen
subsequ
approv
unit
state
food
drug
administr
us
fda
human
use
high
solubl
water
mani
organ
solvent
foster
use
peg
key
excipi
mani
pharmaceut
cosmet
formul
year
uniqu
properti
molecul
flexibl
polym
chain
led
pioneer
work
initi
late
abuchowski
other
field
molecular
modif
biolog
molecul
sinc
coval
attach
peg
protein
peptidebas
therapeut
techniqu
known
pegyl
becom
one
wide
appli
strategi
improv
physicochem
pharmacokinet
properti
labil
compound
pegyl
use
amelior
stabil
solubl
bioavail
immunolog
properti
mani
biolog
compound
lipid
polysaccharid
polynucleotid
recent
complex
live
organ
cell
tissu
virus
monomethoxyl
form
peg
mpeg
contain
singl
hydroxyl
group
activ
inert
methoxi
group
resist
standard
chemic
reaction
gener
use
protein
conjug
figur
first
step
pegyl
process
activ
peg
molecul
prior
protein
conjug
activ
achiev
substitut
singl
hydroxyl
group
end
peg
molecul
electrophil
reactiv
group
coval
link
reactiv
site
protein
figur
succinimidyl
succin
peg
prepar
reaction
mpeg
succin
anhydrid
follow
convers
carboxyl
acid
succinimidyl
ester
linkag
highli
suscept
hydrolysi
polym
attach
protein
reaction
mpeg
tresyl
chlorid
produc
activ
peg
shown
randomli
modifi
protein
virus
liposom
result
heterogen
mixtur
conjug
degrad
linkag
origin
pegyl
scheme
employ
cyanur
chlorid
prepar
activ
peg
attach
protein
multipl
nucleophil
function
group
lysin
serin
tyrosin
cystein
histidin
support
signific
crosslink
aggreg
format
earli
lysin
one
plenti
amino
acid
present
mani
protein
identifi
primari
site
attach
peg
residu
could
modifi
wide
select
chemic
moieti
figur
commonli
use
pegyl
free
group
peptid
protein
protocol
employ
molecul
often
plagu
presenc
impur
nonspecif
attach
residu
allow
inconsist
product
lot
chemistri
also
restrict
low
molecular
weight
polym
attach
bioactiv
molecul
rel
unstabl
tend
degrad
soon
administr
vivo
improv
second
gener
peg
chemistri
minim
diol
contamin
expand
chemic
repertoir
includ
high
molecular
weight
compound
divers
structur
figur
today
pegyl
process
focu
select
amino
acid
thiol
group
cystein
residu
primari
site
attach
therebi
minim
random
attach
peg
protein
surfac
amount
heterogen
conjug
given
prepar
improv
sitespecif
pegyl
reagent
minim
loss
biolog
activ
enhanc
preserv
nativ
protein
structur
complex
branch
second
gener
peg
molecul
also
shown
maintain
ph
thermal
stabil
reduc
immunogen
protect
modifi
protein
proteolysi
much
higher
degre
modifi
first
gener
chemistri
refin
molecul
led
develop
heterofunct
peg
directli
link
protein
interest
anoth
molecul
use
target
specif
cell
tissu
gener
schemat
pegyl
strategi
summar
figur
davi
abuchowski
first
modifi
two
model
protein
bovin
serum
albumin
liver
catalas
methoxypolyethylen
glycol
mpeg
dalton
da
use
cyanur
chlorid
coupl
agent
respect
one
prime
find
peg
properli
coupl
protein
enzym
modifi
product
lose
immunogen
vivo
laid
groundwork
addit
studi
suggest
protein
antigen
modifi
techniqu
may
fail
induc
immun
respons
may
tolerogen
phenomenon
first
report
lee
et
al
intraven
administr
pegyl
ovalbumin
pegova
hour
sensit
dinitrophenyl
ova
dnpova
suppress
primari
antidnpova
antiova
ige
respons
mice
rat
anim
also
respond
poorli
addit
dose
dnpova
contrast
inject
unmodifi
ova
alter
abil
anim
mount
ige
respons
dnpova
addit
report
written
summar
similar
transit
allergen
includ
ragwe
pollen
extract
uricas
lasparaginas
hen
egg
lysozym
bovin
gamma
globulin
antibodi
nonimmunogen
tolerogen
deriv
pegyl
although
shown
repeat
administr
pegyl
allergen
significantli
reduc
igm
igg
ige
antibodi
level
nativ
antigen
also
found
degre
suppress
depend
immunolog
state
time
treatment
natur
allergen
dose
suppress
antibodymedi
respons
best
observ
mice
without
measur
antiallergen
antibodi
weakest
suppress
observ
mice
high
level
antibodi
time
treatment
addit
studi
found
pegyl
allergen
induc
longterm
suppress
antibodi
respons
exampl
administr
pegyl
human
monoclon
immunoglobulin
higg
suppress
antihigg
antibodi
respons
day
seri
seven
inject
immun
antigen
mice
exact
mechan
phenomenon
occur
remain
unknown
adopt
transfer
splenocyt
anim
given
sever
dose
pegyl
compound
anim
suggest
pegmodifi
allergen
activ
antigenspecif
suppressor
cell
sinc
prolifer
suppressor
cell
associ
product
factor
dampen
immun
respons
depend
upon
concentr
circul
antigen
toler
process
slow
antigen
process
extend
halflif
antigen
pegyl
like
play
major
role
immunosuppress
capac
conjug
data
continu
suggest
pegyl
biomolecul
less
immunogen
nativ
counterpart
mani
interest
prevent
immunoreject
transplant
began
appli
process
intact
viabl
cell
tissu
modif
type
type
b
human
red
blood
cell
rbc
mpeg
compromis
structur
function
viabil
cell
prevent
agglutin
antia
antib
antisera
respect
pegyl
ovin
rbc
prolong
surviv
transfus
mice
pegyl
lymphocyt
inhibit
mhc
class
ii
activ
prolifer
cell
demonstr
vivo
model
transfusionassoci
graft
versu
host
diseas
adopt
transfer
pegyl
splenocyt
isol
mice
lethal
irradi
balbc
mice
extend
surviv
time
day
pegyl
reduc
prolifer
donor
cell
popul
suggest
loss
cell
respons
like
due
disrupt
interact
cell
antigen
present
cell
necessari
mount
immun
respons
also
suggest
weak
ineffect
costimul
alloreact
cell
induc
apoptosi
lead
toler
donor
tissu
phenomenon
exemplifi
diabet
rat
model
pegyl
improv
pancreat
islet
viabil
facilit
engraft
reestablish
blood
glucos
homeostasi
addit
studi
demonstr
pegyl
effici
block
recognit
transplant
immun
cell
allow
remain
stabli
function
diabet
recipi
sever
week
approv
pegademas
treatment
sever
combin
immunodefici
diseas
scid
us
fda
earli
illustr
potenti
pegyl
significantli
impact
modern
therapeut
halflif
product
bovin
adenosin
deaminas
randomli
modifi
kda
peg
molecul
increas
less
min
hr
conjug
counterpart
along
fact
modifi
enzym
prepar
could
evok
time
activ
per
millilit
red
blood
cell
alon
mark
notabl
progress
area
enzym
replac
therapi
minim
number
dose
need
achiev
therapeut
effect
elimin
need
blood
transfus
avoid
risk
iron
overload
transfusionassoci
viral
infect
similar
manner
therapeut
use
lasparaginas
acut
lymphoblast
leukemia
hinder
fact
frequent
intramuscular
inject
necessari
therapeut
efficaci
also
induc
strong
hypersensit
reaction
render
enzym
ineffect
mani
patient
coval
attach
kda
peg
enzym
four
year
later
reduc
immunogen
necess
frequent
dose
allow
success
use
hypersensit
unmodifi
enzym
within
last
year
improv
polym
homogen
pegyl
chemistri
produc
mani
potent
wellcharacter
proteinbas
therapeut
therapeut
pegyl
protein
current
market
unit
state
europ
summar
tabl
two
market
product
pegyl
interferon
alpha
pegintron
schere
plough
pegasi
roch
illustr
differ
peg
chemistri
affect
pharmacokinet
profil
biolog
activ
protein
pegintron
contain
singl
chain
peg
attach
via
urethan
bond
although
modif
significantli
extend
elimin
halflif
reduc
clearanc
protein
tabl
conjug
hydrolyt
unstabl
plasma
store
ambient
temperatur
activ
prepar
rel
unmodifi
protein
contrast
pegasi
contain
branch
kda
peg
molecul
attach
lysin
residu
via
amid
bond
conjug
greater
vitro
vivo
stabil
significantli
longer
half
life
pegintron
reduc
clearanc
protein
factor
overshadow
fact
modifi
protein
retain
rel
activ
unmodifi
protein
tabl
despit
differ
product
greater
antivir
action
nativ
counterpart
reduc
administr
schedul
three
time
week
weekli
granulocytecoloni
stimul
factor
gcsf
conjug
peg
order
increas
overal
size
molecul
case
pegfilgrastim
pegyl
gcsf
increas
size
minim
renal
clearanc
drug
prolong
circul
time
stimul
prolifer
differenti
neutrophil
turn
aid
clear
compound
therapeut
level
attain
certolizumab
pegol
fragment
human
antitumor
necrosi
monoclon
antibodi
link
branch
kda
peg
maleimid
singl
cystein
residu
demonstr
prolong
circul
time
blood
singl
monthli
subcutan
inject
suffici
therapeut
efficaci
addit
increas
size
molecul
pegyl
allow
preferenti
accumul
inflam
tissu
therapeut
effect
primarili
need
nonvir
gene
transfer
method
dna
formul
cation
lipid
andor
polym
creat
dens
particl
deliv
target
cell
physic
mean
direct
inject
electropor
gene
gun
particl
howev
often
rapidli
sequest
reticuloendotheli
system
re
remov
bloodstream
within
minut
system
administr
pegyl
primarili
use
reduc
rate
vector
clear
improv
therapeut
efficaci
achiev
pegyl
prepar
contain
branch
polyplex
well
simpl
dnachitosan
mixtur
case
modif
minim
aggreg
format
physiolog
condit
prolong
circul
time
therebi
reduc
uptak
macrophag
improv
overal
transduct
effici
system
numer
report
shown
pegyl
also
reduc
bind
dna
complex
plasma
protein
minim
toxic
improv
stabil
solubl
turn
transfect
effici
nonvir
prepar
result
studi
data
accumul
clinic
trial
viral
vector
soon
prompt
develop
pegyl
strategi
virus
although
viral
vector
unlik
nonvir
counterpart
extrem
effici
induc
transgen
express
cellular
target
clinic
util
hinder
signific
immunogen
toxic
coval
modif
protein
contain
viru
coat
peg
shown
improv
physicochem
biolog
properti
sever
recombin
virus
use
gene
transfer
tabl
includ
adenoassoci
viru
aav
pseudotyp
lentiviru
retroviru
baculoviru
pegyl
also
use
modifi
influenza
virosom
viruslik
particl
synthes
capsid
protein
minim
host
immunolog
respons
result
mani
viral
vector
minim
signific
effort
develop
pegyl
protocol
one
potent
vector
highli
character
toxic
profil
date
adenoviru
despit
fact
recombin
adenovirus
infect
divid
nondivid
cell
capac
accommod
larg
dna
insert
readili
produc
larg
quantiti
high
puriti
clinic
use
significantli
hinder
strong
innat
adapt
immun
respons
viral
protein
compound
fact
viru
enter
cell
sever
receptor
integrin
heparan
sulfat
proteoglycan
coxsacki
adenoviru
receptor
car
distribut
wide
throughout
bodi
lead
nonspecif
transgen
express
undesir
side
effect
thrombocytopenia
intens
periport
polymorphonuclear
lymphocyt
infiltr
elev
liver
enzym
thu
signific
effort
put
forth
develop
pegyl
protocol
adenoviru
otherwis
highli
effici
vector
gene
transfer
pegyl
adenoviru
initi
achiev
use
monofunct
peg
mpeg
monomethoxypolyethylen
glycol
activ
tresyl
chlorid
tmpeg
succinimidyl
succin
sspeg
cyanur
chlorid
ccpeg
react
termin
lysin
residu
viru
capsid
protein
figur
earli
studi
reveal
modif
tmpeg
compromis
viru
titer
hour
reaction
period
modif
sspeg
reduc
titer
prepar
modifi
ccpeg
chemistri
retain
origin
titer
minut
conjug
process
complet
later
found
dramat
loss
titer
due
extens
crosslink
polym
multipl
viru
capsid
subsequ
format
larg
aggreg
despit
initi
loss
infecti
titer
pegyl
process
prepar
maintain
titer
significantli
higher
unmodifi
viru
storag
extend
period
time
pegyl
adenoviru
prior
microencapsul
poli
lacticcoglycol
acid
plga
block
copolym
prevent
inactiv
viru
microencapsul
process
result
improv
transfect
effici
respect
unmodifi
viru
use
process
investig
reveal
modif
prevent
viru
aggreg
within
acid
environ
creat
degrad
microspher
prevent
shearinduc
damag
viru
capsid
homogen
process
although
earli
studi
report
pegyl
increas
transduct
factor
lung
factor
liver
also
found
excess
pegyl
could
critic
damag
structur
function
viru
limit
transduct
effici
exampl
increas
viral
amin
mpeg
molar
ratio
reduc
rel
transduct
effici
viru
addit
studi
reveal
transduct
fell
free
amin
viru
modifi
peg
respect
realiz
number
peg
molecul
attach
capsid
protein
profoundli
affect
perform
viru
vitro
vivo
much
effort
put
forth
develop
assay
character
physic
properti
vector
accur
determin
degre
modif
occur
within
given
prepar
peg
molecul
ad
viru
surfac
mask
protein
residu
dictat
overal
charg
rel
solubl
particl
increas
hydrodynam
radiu
accord
size
peg
thu
initi
character
profil
pegyl
adenovirus
includ
assay
design
assess
broad
chang
physic
properti
viru
particl
size
zeta
potenti
pegdextran
partit
coeffici
zeta
potenti
analysi
reveal
pegyl
reduc
neg
charg
viru
capsid
mv
unmodifi
nativ
viru
mv
conjug
tmpeg
sspeg
ccpeg
respect
partit
coeffici
pegviru
conjug
aqueou
pegdextran
twophas
system
k
found
shift
unmodifi
viru
viru
conjug
tmpeg
sspeg
ccpeg
chemistri
respect
although
assay
abl
confirm
viru
particl
modifi
pegyl
process
complet
accur
assess
degre
modif
chang
particl
size
viru
found
correl
degre
modif
one
report
addit
kda
peg
avail
site
adenoviru
capsid
increas
diamet
particl
approxim
effort
focus
upon
assess
number
unmodifi
amino
group
remain
viru
prior
pegyl
process
use
tradit
fluorescamin
assay
measur
fluoresc
proport
free
lysin
amino
group
viru
capsid
pegbiotin
enzymelink
immunosorb
assay
elisa
indirectli
quantifi
amount
biotinlabel
peg
associ
viru
particl
use
avidinhorseradish
peroxidas
detect
system
pair
assay
analyt
techniqu
capillari
zone
electrophoresi
high
pressur
liquid
chromatographi
hplc
subtl
chang
physic
properti
individu
capsid
protein
measur
chang
placement
peak
andor
peak
size
figur
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
barium
iodid
stain
allow
one
visual
specif
viru
protein
link
peg
measur
chang
molecular
weight
associ
new
pegconjug
figur
improv
accuraci
chemic
profil
pegyl
virus
assist
assess
reproduc
reliabl
pegyl
process
prior
clinic
test
mention
previous
one
benefit
pegyl
therapeut
protein
modif
prolong
circul
time
allow
administr
singl
daili
dose
achiev
full
therapeut
effect
given
system
halflif
unmodifi
adenoviru
less
minut
kinet
pegyl
adenoviru
initi
describ
alemani
et
al
indic
clearanc
rate
modifi
viru
reduc
factor
respect
unmodifi
viru
mice
similarli
report
pegyl
reduc
system
clearanc
helperdepend
adenoviru
approxim
nonhuman
primat
circul
time
pegyl
adenoviru
target
endotheli
cell
blood
found
significantli
longer
unmodifi
viru
system
administr
mice
evidenc
increas
area
plasma
concentrationtim
curv
auc
factor
halflif
pegyl
adenoviru
also
increas
profoundli
degre
modif
tabl
plasma
halfliv
adenovirus
link
kda
peg
ratio
min
respect
wherea
unmodifi
ad
calcul
half
life
min
mice
increas
molecular
weight
peg
also
prolong
time
viru
remain
system
circul
tabl
plasma
level
adenoviru
conjug
kda
peg
modif
ratio
time
unmodifi
viru
tine
viru
coupl
kda
peg
modif
ratio
minut
intraven
administr
mice
similarli
report
circul
genom
level
viru
modifi
kda
peg
fold
higher
unmodifi
viru
earli
minut
later
hour
time
system
administr
mice
remov
adenoviru
bloodstream
rapid
uptak
liver
intraven
inject
caus
nonspecif
chargemedi
interact
protein
cell
notabl
compon
reticuloendotheli
system
re
also
known
adenoviru
preferenti
accumul
liver
spleen
rodent
model
nonhuman
primat
given
system
contribut
significantli
toxic
associ
vector
although
exact
mechan
peg
prolong
circul
time
blood
current
known
thought
protrus
long
chain
peg
molecul
viru
surfac
play
critic
role
minim
cellular
interact
limit
access
liver
parenchyma
subsequ
extend
circul
halflif
inde
manner
pegyl
extend
viru
one
must
also
reason
transduct
effici
also
compromis
report
vitro
howev
other
found
conjug
viru
kda
peg
compromis
hepat
transduct
effici
first
gener
helper
depend
adenovirus
mice
one
reason
may
longer
circul
time
prolong
viru
contact
liver
addit
vitro
data
figur
unpublish
data
studi
rodent
suggest
pegyl
viru
retain
liver
transduct
effici
enter
cell
via
heparan
sulfat
proteoglycan
receptor
hspgr
primari
mean
viru
enter
hepatocyt
vivo
interact
blood
factor
includ
protein
c
pc
factor
vii
fvii
factor
ix
fix
factor
x
fx
facilit
bind
viru
receptor
recent
studi
report
pegyl
reduc
transduct
effici
helperdepend
adenoviru
liver
nonhuman
primat
suggest
data
gener
rodent
model
may
predict
modifi
virus
perform
clinic
although
mechan
underli
differ
hepat
transduct
effici
pegyl
viru
speci
unclear
speciesspecif
differ
liver
fenestr
bind
properti
platelet
blood
compon
modifi
viru
may
attribut
find
nonhuman
primat
although
averag
diamet
fenestra
mous
baboon
similar
nm
respect
number
fenestra
baboon
liver
less
mous
factor
thu
smaller
size
lower
densiti
fenestra
may
anatom
barrier
hepatocyt
transduct
nonhuman
primat
may
also
explain
reduc
hepat
transduct
effici
viru
modifi
high
molecular
weight
peg
high
peg
densiti
report
mice
adenovirusinduc
toxic
caus
immun
respons
viru
capsid
protein
occur
shortli
system
administr
sever
anim
model
human
coval
attach
peg
viru
capsid
significantli
allevi
virusinduc
hepatotox
cytotox
mice
serum
alanin
aminotransferas
alt
indic
hepatotox
reduc
mice
given
pegyl
first
gener
helperdepend
adenoviru
factor
respect
anim
given
unmodifi
viru
similar
result
also
found
serum
aspart
aminotransferas
ast
anoth
indic
hepatotox
nonhuman
primat
serum
lactat
dehydrogenas
ldh
indic
tissu
organ
damag
also
follow
similar
trend
indic
pegyl
reduc
adenovirusassoci
toxic
nonhuman
primat
one
might
reason
observ
simpli
due
fact
viru
effici
transduc
primat
liver
addit
data
studi
suggest
reduct
uptak
pegyl
viru
spleen
subsequ
drop
cytokin
releas
see
section
respons
improv
toxic
profil
pegyl
vector
anim
model
abnorm
associ
blood
coagul
includ
prolong
clot
time
reduct
platelet
increas
ddimer
level
observ
administr
adenoviru
sever
anim
model
human
signific
drop
platelet
count
observ
mice
three
day
administr
unmodifi
helperdepend
viru
anim
treat
pegyl
viru
experi
chang
platelet
count
baselin
level
similarli
conjug
second
gener
adenoviru
sspeg
tmpeg
complet
prevent
thrombocytopenia
recent
studi
mice
demonstr
platelet
count
unaffect
administr
pegyl
viru
dose
viral
genom
vg
kg
slight
decreas
detect
dose
vgkg
studi
pegyl
also
reduc
product
ddimer
factor
investig
illustr
pegyl
reduc
bind
viru
platelet
erythrocyt
taken
togeth
suggest
steric
hindranc
associ
polym
prevent
interact
platelet
turn
disrupt
clot
cascad
also
limit
endotheli
cellmedi
platelet
activ
clearanc
lead
reduc
ddimer
format
subsequ
thrombocytopenia
differ
bind
may
also
explain
fact
reduct
platelet
note
baboon
hour
administr
vpkg
unmodifi
pegyl
helperdepend
viru
transient
drop
return
baselin
within
hour
baboon
given
pegyl
viru
platelet
remain
low
throughout
studi
anim
given
unmodifi
viru
ddimer
affect
manner
toxic
associ
recombin
adenovirus
aris
innat
adapt
immun
respons
viru
develop
three
phase
anim
model
human
first
phase
caus
interact
adenoviru
capsid
kupffer
cell
macrophag
dendrit
cell
occur
earli
hour
system
administr
continu
four
day
result
releas
proinflammatori
cytokin
chemokin
includ
tumornecrosi
rant
gener
circul
recruit
effector
cell
lead
neutrophildepend
hepat
injuri
progress
toward
second
phase
inflammatori
process
phase
occur
day
administr
character
remov
vectorinfect
cell
activ
lymphocyt
lead
shortterm
transgen
express
selflimit
inflamm
liver
high
viral
load
progress
sever
liver
necrosi
dissemin
intravascular
coagulopathi
bleed
case
system
inflammatori
respons
syndrom
condit
character
multiorgan
failur
sepsi
trauma
last
phase
humor
immun
respons
character
product
antibodi
rapidli
clear
viru
circul
prevent
success
gene
transfer
upon
readministr
variou
strategi
evalu
circumv
cellular
humor
immun
respons
gener
adenovir
vector
immunosuppress
agent
cyclophosphamid
cyclosporin
disrupt
costimulatori
interact
cell
b
cell
use
ligand
antibodi
effect
blunt
immun
respons
extend
length
transgen
express
howev
approach
deem
unsuit
practic
sinc
impair
immun
microb
produc
seriou
unwant
side
effect
delet
viral
earli
late
gene
helperdepend
adenovirus
reduc
cellmedi
immun
respons
result
high
level
longterm
transgen
express
howev
acut
toxic
neutral
antibodi
still
detect
treatment
vector
recent
effort
employ
genet
substitut
fiber
hexon
capsid
protein
rare
nonhuman
adenoviru
serotyp
shown
dampen
innat
respons
subsequ
releas
inflammatori
cytokin
although
virus
construct
approach
term
seroswitch
minim
affect
antiadenoviru
type
neutral
antibodi
success
given
sever
time
difficult
produc
riordan
et
al
first
show
coval
attach
polyethylen
glycol
adenoviru
capsid
protein
straightforward
practic
strategi
prevent
neutral
antibodi
nab
recogn
viru
surfac
antigen
conjug
viru
tmpeg
improv
vitro
transduct
effici
presenc
neutral
antibodi
fold
respect
unmodifi
viru
strike
find
studi
administr
pegyl
viru
mice
previous
expos
unmodifi
viru
produc
transgen
express
level
equival
found
anim
sinc
mani
group
report
similar
result
pegyl
attenu
acut
toxic
associ
innat
immun
respons
reduc
product
proinflammatori
cytokin
chemokin
infiltr
neutrophil
liver
earli
report
demonstr
mice
treat
pegyl
first
gener
helper
depend
adenovirus
serum
level
time
lower
respect
seen
mice
given
unmodifi
viru
hour
treatment
timepoint
serum
anim
treat
pegyl
viru
fold
lower
anim
treat
unmodifi
viru
pegyl
also
shown
reduc
baselin
level
character
cytokin
releas
profil
mice
reveal
pegyl
viru
produc
similar
kinet
profil
cytokin
anim
receiv
unmodifi
viru
mean
level
still
peak
hour
howev
pegyl
first
gener
helperdepend
virus
significantli
reduc
cytokin
level
earli
hour
treatment
well
hour
factor
respect
similar
report
rodent
level
also
found
reduc
approxim
nonhuman
primat
given
singl
intraven
dose
vpkg
dose
pegyl
helperdepend
adenoviru
studi
reduc
factor
detect
anim
given
pegyl
vector
realtim
rtpcr
analysi
indic
hepat
gene
express
chemokin
includ
monocyt
chemoattract
macrophag
inflammatori
macrophag
inflammatori
interferoninduc
lipopolysaccharideinduc
cxc
chemokin
lix
significantli
reduc
mice
tail
vein
inject
pegyl
viru
neutrophil
infiltr
liver
mice
reduc
factor
respect
given
unmodifi
viru
vitro
mechanist
studi
reveal
macrophag
infect
pegyl
viru
fail
produc
studi
report
vector
uptak
macrophag
kupffer
cell
vitro
vivo
significantli
hinder
pegyl
taken
togeth
one
may
attribut
reduct
immunogen
inflict
upon
adenoviru
pegyl
process
due
fact
polym
prevent
uptak
process
viru
antigen
present
cell
addit
studi
pegyl
adenovirus
reveal
modif
dramat
attenu
cellular
immun
respons
signific
reduct
cytotox
lymphocyt
product
note
singl
intratrach
intraven
dose
pegyl
viru
mice
modif
viru
peg
alon
peg
peptid
specif
fibroblast
growth
factor
receptor
reduc
secret
marker
respons
might
expect
transgen
express
profil
achiev
sever
pegyl
vector
significantli
extend
beyond
commonli
seen
unmodifi
virus
seen
nativ
viru
transgen
express
intratrach
instil
pegyl
viru
also
peak
mice
day
continu
day
long
nativ
viru
dwindl
day
treatment
similarli
transgen
express
extend
day
singl
intraven
inject
pegyl
viru
mous
although
exact
mechan
pegyl
dampen
cell
respons
identifi
like
polym
alter
process
present
viral
antigen
prevent
cell
recogn
viral
epitop
also
possibl
peg
modif
redirect
vector
away
antigenpres
cell
apc
fact
sever
report
describ
unsuccess
readministr
pegyl
viru
mice
treat
viru
modifi
peg
chemistri
chang
chemistri
polym
reestablish
transgen
express
suggest
shield
tradit
immunogen
peptid
sequenc
pegyl
capsid
protein
may
induc
process
recognit
sequenc
close
associ
polym
initi
effort
chemic
modifi
adenoviru
capsid
protein
facilit
infect
specif
cell
type
involv
coupl
receptorspecif
ligand
folat
antiadenoviru
antibodi
mix
nativ
viru
altern
approach
involv
genet
introduc
fiber
protein
adenoviru
serotyp
vector
incorpor
home
ligand
viru
capsid
howev
limit
modest
product
yield
larg
scale
potenti
gener
new
immun
respons
alter
vector
pegyl
chemistri
advanc
bifunt
molecul
evalu
abil
link
viru
tissu
cellspecif
ligand
strategi
approach
summar
figur
coupl
biolog
select
peptid
adenoviru
capsid
use
bifunct
peg
first
report
romanczuk
colleagu
modif
viru
peg
peptid
specif
differenti
ciliat
airway
epitheli
cell
improv
transduct
effici
target
fourfold
similar
find
report
pegyl
vector
conjug
fibroblast
growth
factor
fgf
vitro
vivo
adenoviru
modifi
peg
improv
transduct
human
ovarian
cancer
cell
vitro
factor
respect
unmodifi
viru
similar
result
observ
vivo
tumorbear
scid
mice
retarget
pegyl
viru
fgf
also
found
improv
transduct
fold
murin
human
muscl
cell
vitro
factor
skelet
muscl
mdx
mice
sinc
rgd
secondari
mediat
adenoviru
cell
entri
util
home
ligand
demonstr
sever
group
respect
unmodifi
viru
rgdpegad
show
higher
level
gene
express
carposit
neg
cell
suggest
modif
dampen
carmedi
infect
target
cell
enhanc
abil
viru
infect
cell
integrin
pathway
addit
improv
gene
transfer
endotheli
cell
mice
delayedtyp
hypersensit
human
breast
cancer
cell
achiev
coupl
antieselectin
antibodi
folat
human
epiderm
growth
factor
egf
pegyl
viru
respect
addit
improv
cellspecif
transduct
effici
simpl
approach
also
offer
sever
benefit
describ
includ
shield
adenoviru
immun
system
improv
half
life
pharmacokinet
paramet
viru
minim
safeti
concern
aris
respect
use
genet
chemic
modifi
virus
clinic
inher
abil
induc
strong
innat
adapt
immun
respons
adenovirus
success
employ
carrier
recombin
vaccin
one
signific
drawback
howev
fact
signific
portion
human
popul
mark
level
antibodi
commonli
use
adenoviru
serotyp
use
nonhuman
serotyp
chimpanze
adenoviru
rare
human
serotyp
serotyp
induc
strong
immun
respons
face
preexist
immun
howev
addit
work
address
issu
associ
safeti
largescal
product
vector
order
signific
data
gener
pegyl
virus
demonstr
vector
effici
induc
transgen
express
face
preexist
immun
technolog
also
found
applic
respect
vaccin
develop
earli
work
area
shown
oral
vaccin
pegyl
adenoviru
moder
improv
bcell
mediat
immun
respons
ebola
glycoprotein
mice
preexist
immun
viru
modifi
high
molecular
weight
peg
also
shown
induc
strong
cellular
humor
immun
respons
transgeneantigen
mice
previous
expos
unmodifi
adenoviru
primeboost
approach
prime
viru
modifi
kda
peg
enabl
unmodifi
pegyl
vector
induc
stronger
cell
respons
encod
antigen
respect
achiev
unmodifi
viru
alon
although
result
promis
work
pegyl
vector
vaccin
develop
clearli
earli
stage
exact
mechan
vector
reduc
immunogen
profil
induc
strong
antiantigen
immun
respons
current
unknown
sinc
earli
studi
pegyl
virus
initi
year
signific
number
report
literatur
made
clear
coval
attach
mani
differ
form
poli
ethylen
glycol
significantli
attenu
immun
respons
viru
capsid
improv
transduct
effici
tissu
alon
addit
home
ligand
viru
modifi
heterofunct
chemistri
mice
nonhuman
primat
addit
bodi
evid
support
notion
much
toxic
associ
use
adenoviru
also
elimin
modif
despit
favor
attribut
chemic
modifi
virus
consider
clinic
use
mani
preclin
studi
date
suggest
sever
variabl
molecular
weight
shape
polym
well
conjug
chemistri
profoundli
dictat
immunolog
pharmacokinet
profil
adenoviru
refin
pegyl
chemistri
improv
sitespecif
attach
viru
capsid
home
ligand
minim
potenti
gener
mixtur
virus
differ
peg
ligand
viru
ratio
evalu
valid
addit
highli
sensit
assay
character
pegyl
virus
larg
scale
pegyl
process
vital
ensur
protocol
reproduc
prepar
consist
vector
modifi
degre
free
extran
reaction
byproduct
also
import
realiz
studi
determin
exact
mechan
pegyl
blunt
antiadenoviru
immun
respons
evid
polym
prevent
interact
antigen
present
cell
studi
use
modifi
vector
vaccin
purpos
suggest
immun
respons
encod
antigen
due
increas
uptak
process
vector
antigen
present
cell
addit
report
suggest
slight
somewhat
delay
immun
respons
modifi
virus
prevent
repeat
dose
outlin
previous
pegyl
initi
employ
techniqu
induc
immunolog
toler
given
antigen
yet
consid
pegyl
adenovirus
date
evalu
vector
multipl
dose
requir
